Genmab — Juni 2023
-
Hav en aldeles fremragende weekend!
-
https://www.novartis.com/news/media-releases/novartis-publishes-new-five-year-efficacy-data-kesimpta-ofatumumab-treatment-relapsing-multiple-sclerosis?utm_source=twitter&utm_medium=social&utm_campaign=2023-media-release&utm_term=na&utm_content=static-image-news Novartis publishes new five-year efficacy data on Kesimpta
(ofatumumab) for the treatment of relapsing multiple sclerosis -
“resulted in an increase in the number of patients with relapsing forms of multiple sclerosis (RMS) achieving NEDA-3 (no evidence of disease activity) for up to five years in the ALITHIOS open-label extension study” Kunne ligne cure for nogle. Fantastisk !
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind